FDA's notice for a May 16 public meeting say it intends to ensure its "regulatory framework is flexible enough to adequately evaluate product safety without unnecessarily restricting innovation." But FDA makes clear adherence with its NDI notification requirement is focus of the spurring improvement in VMS product industry's overall compliance with regulatory framework established by DSHEA.
Improving compliance with the US Food and Drug Administration's premarket notification requirement for dietary ingredients is the focal point of the agency's discussion on strengthening its dietary supplement industry oversight.
The FDA's notice for a May 16 public meeting in College Park, Md., explains that the agency intends to ensure...